HomeCompareBKCYF vs PFE

BKCYF vs PFE: Dividend Comparison 2026

BKCYF yields 7.19% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BKCYF wins by $52667.02M in total portfolio value
10 years
BKCYF
BKCYF
● Live price
7.19%
Share price
$10.27
Annual div
$0.74
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52667.07M
Annual income
$51,296,436,910.13
Full BKCYF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BKCYF vs PFE

📍 BKCYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBKCYFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BKCYF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BKCYF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BKCYF
Annual income on $10K today (after 15% tax)
$611.11/yr
After 10yr DRIP, annual income (after tax)
$43,601,971,373.61/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, BKCYF beats the other by $43,601,949,053.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BKCYF + PFE for your $10,000?

BKCYF: 50%PFE: 50%
100% PFE50/50100% BKCYF
Portfolio after 10yr
$26333.56M
Annual income
$25,648,231,584.43/yr
Blended yield
97.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BKCYF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-0.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BKCYF buys
0
PFE buys
0
No recent congressional trades found for BKCYF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBKCYFPFE
Forward yield7.19%6.13%
Annual dividend / share$0.74$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$52667.07M$49.6K
Annual income after 10y$51,296,436,910.13$26,258.71
Total dividends collected$52573.03M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: BKCYF vs PFE ($10,000, DRIP)

YearBKCYF PortfolioBKCYF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,138$1,437.92$9,153$693.39+$3.0KBKCYF
2$16,250$3,262.30$8,593$849.25+$7.7KBKCYF
3$25,551$8,163.49$8,336$1,066.78+$17.2KBKCYF
4$51,332$23,992.62$8,437$1,384.80+$42.9KBKCYF
5$145,022$90,096.29$9,013$1,875.40+$136.0KBKCYF
6$630,943$475,770.25$10,306$2,680.72+$620.6KBKCYF
7$4,544,132$3,869,022.47$12,820$4,101.38+$4.53MBKCYF
8$56,946,666$52,084,445.23$17,673$6,826.70+$56.93MBKCYF
9$1,280,966,119$1,220,033,185.74$27,543$12,591.86+$1280.94MBKCYF
10$52,667,070,657$51,296,436,910.13$49,560$26,258.71+$52667.02MBKCYF

BKCYF vs PFE: Complete Analysis 2026

BKCYFStock

Bank of Cyprus Holdings Public Limited Company, through its subsidiaries, provides banking, financial, and insurance services. It offers current, savings, notice, instant access, and fixed deposits; housing, student, consumer, business and business premises, term, and home or investment loans; and asset finance, factoring, trade facilities, European financial, project finance, shipping finance, and syndicated and corporate lending services, as well as hire purchase services for car and equipment. The company also provides debit, credit, prepaid, and special cards; reward programs; digital products; digital banking, and payments and services; motor, home, business, life, create capital, and health insurance products; SME guarantee facility services; day to day banking services; investment banking and brokerage, asset and wealth management, market execution and hedging, and structured and funding solutions; investment products and services; and custody and depositary services. In addition, it is involved in the property trading and development activities; land development and operation of a golf resort; management administration and safekeeping of UCITS units; administration of guarantees and holding of real estate properties; collection of the existing portfolio of receivables, including third party collections; and provision of card processing transaction, auction, and secretarial services. As of June 30, 2022, the company operated 86 branches in Cyprus. Bank of Cyprus Holdings Public Limited Company was founded in 1899 and is headquartered in Nicosia, Cyprus.

Full BKCYF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BKCYF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BKCYF vs SCHDBKCYF vs JEPIBKCYF vs OBKCYF vs KOBKCYF vs MAINBKCYF vs JNJBKCYF vs MRKBKCYF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.